A Phase 3b, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection
Phase of Trial: Phase III
Latest Information Update: 27 May 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 19 May 2017 Status changed from active, no longer recruiting to completed.
- 28 Feb 2017 Planned End Date changed from 1 Aug 2017 to 1 May 2017.
- 12 Sep 2016 Status changed from recruiting to active, no longer recruiting.